Key terms
About TXG
10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell transcriptomics, single cell genomics, single cell epigenomes, linked-reads genomics and spatial transcriptomics. The company’s products include Single Cell Gene Expression, Immune Profiling, ATAC, and Genome. The company was founded by Serge Saxonov, Ben Hindson and Kevin D. Ness on July 2, 2012 and is headquartered in Pleasanton, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest TXG news
Apr 04
8:15pm ET
Cathie Wood’s ARK Investment bought 138K shares of 10x Genomics today
Mar 21
8:47pm ET
Cathie Wood’s ARK Investment bought 241K shares of 10x Genomics today
Mar 13
4:10pm ET
10x Genomics begins commercial shipments of Chromium GEM-X products
Feb 26
8:03pm ET
Cathie Wood’s ARK Investment bought 157K shares of 10x Genomics today
Feb 16
5:40pm ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Gilead Sciences (GILD), Travere Therapeutics (TVTX) and 10x Genomics (TXG)
Feb 16
8:10am ET
10x Genomics price target lowered to $63 from $68 at Stifel
Feb 16
8:06am ET
Stifel Nicolaus Sticks to Its Buy Rating for 10x Genomics (TXG)
Feb 16
7:20am ET
Maintaining Buy Rating on 10x Genomics Amidst Strong Xenium Sales and Promising Future Product Launches
Feb 16
6:58am ET
10x Genomics (TXG) Initiated with a Buy at Barclays
Feb 16
5:09am ET
10x Genomics price target lowered to $65 from $70 at Canaccord
Feb 16
5:07am ET
Hold Rating Reiterated Amid Mixed Financial Performance and Market Volatility
Feb 15
10:25pm ET
10x Genomics Poised for Growth: Buy Rating Affirmed Amid Strong Spatial Segment Performance and Solid Financial Outlook
Feb 15
4:12pm ET
10x Genomics sees FY23 revenue $670M-$690M, consensus $702.06M
Feb 15
4:12pm ET
10x Genomics reports Q4 EPS (41c), consensus (36c)
Feb 12
2:58pm ET
Canaccord still bullish on 10x Genomics, PacBio despite reducing 2024 estimates
Feb 07
9:02am ET
10x Genomics price target lowered to $60 from $65 at Deutsche Bank
Jan 24
7:18am ET
10x Genomics price target raised to $55 from $45 at Barclays
Jan 22
2:10pm ET
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), 10x Genomics (TXG) and Altimmune (ALT)
Jan 09
5:11am ET
Analysts Offer Insights on Healthcare Companies: NeuroPace (NPCE), Alignment Healthcare (ALHC) and 10x Genomics (TXG)
Jan 08
12:07pm ET
10x Genomics’s preliminary Q4 results ahead of Street estimates, says Canaccord
Jan 08
9:05am ET
10x Genomics sees FY23 revenue approximately $618.7M, consensus $614.69M
Jan 08
9:04am ET
10x Genomics sees Q4 revenue approximately $184M, consensus $179M
No recent press releases are available for TXG
TXG Financials
Key terms
Ad Feedback
TXG Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
TXG Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
